Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Non-Current Debt (2016 - 2021)

Arcadia Biosciences' Non-Current Debt history spans 7 years, with the latest figure at $78000.0 for Q3 2021.

  • For Q3 2021, Non-Current Debt fell 96.94% year-over-year to $78000.0; the TTM value through Sep 2021 reached $78000.0, down 96.94%, while the annual FY2020 figure was $2.1 million, 1867.29% up from the prior year.
  • Non-Current Debt reached $78000.0 in Q3 2021 per RKDA's latest filing, down from $87000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $23.1 million in Q1 2017 to a low of $78000.0 in Q3 2021.
  • Average Non-Current Debt over 4 years is $4.7 million, with a median of $130000.0 recorded in 2020.
  • Peak YoY movement for Non-Current Debt: soared 2154.87% in 2020, then crashed 96.94% in 2021.
  • A 4-year view of Non-Current Debt shows it stood at $21.1 million in 2017, then tumbled by 99.49% to $107000.0 in 2019, then skyrocketed by 1867.29% to $2.1 million in 2020, then crashed by 96.29% to $78000.0 in 2021.
  • Per Business Quant, the three most recent readings for RKDA's Non-Current Debt are $78000.0 (Q3 2021), $87000.0 (Q2 2021), and $96000.0 (Q1 2021).